Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion

British Journal of Ophthalmology

Volumn 99, Issue 2, 2015, Pages 215-219

  Shimura, Masahiko ^a   Yasuda, Kanako ^a  

^a NTT East Tohoku Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BROMFENAC; SODIUM CHLORIDE; ANGIOGENESIS INHIBITOR; BENZOPHENONE DERIVATIVE; BROMOBENZENE; EYE DROPS; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MACULAR EDEMA; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; PATIENT MONITORING; PROSPECTIVE STUDY; REMISSION; RETINA FOVEA; RETINAL THICKNESS; TREATMENT DURATION; TREATMENT OUTCOME; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; COMPLICATION; INTERVENTION STUDY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINAL VEIN OCCLUSION; RETREATMENT; TOPICAL DRUG ADMINISTRATION; VISUAL FIELD;

ADMINISTRATION, TOPICAL; AGED; ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL, HUMANIZED; BENZOPHENONES; BROMOBENZENES; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERVENTION STUDIES; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; RETREATMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VISUAL FIELDS;

EID: 84921525184     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2013-304720     Document Type: Article

References (26)

1. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-31.
2. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974;78:OP178-92.
3. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82.
4. Battaglia Parodi M, Saviano S, Bergamini L, et al. Grid laser treatment of macular edema in macular branch retinal vein occlusion. Doc Ophthalmol 1999;97:427-31.
5. Battaglia Parodi M, Saviano S, Ravalico G. Grid laser treatment in macular branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 1999;237:1024-7.
6. Ehlers JP, Fekrat S. Retinal vein occlusion: beyond the acute event. Surv Ophthalmol 2011;56:281-99.
7. Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion:results after 12 months and multiple regression analysis. Retina 2009;29:1242-8.
8. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518-22.
9. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-6.
10. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study. Ophthalmology 2014;121:209-19.
11. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 2009;54:372-400.
12. Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology 2011;118:1827-33.
13. Flaxel C, Schain MB, Hamon SC, et al. Prospective randomized controlled trial of combination ranibizumab (Lucentis) and bromfenac (Xibrom) for neovascular age-related macular degeneration: a pilot study. Retina 2012;32:417-23.
14. Gomi F, Sawa M, Tsujikawa M, et al. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina 2012;32:1804-10.
15. Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther 2008;24:392-8.
16. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci 2009;50:1025-32.
17. Kreutzer TC, Alge CS, Wolf AH, et al. Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351-5.
18. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010;21:178-83.
19. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-5.
20. Ramezani A, Entezari M, Moradian S, et al. Intravitreal triamcinolone for acute branch retinal vein occlusion: a randomized clinical trial. J Ophthalmic Vis Res 2011;6:101-8.
21. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular Edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28.
22. Tanito M, Hara K, Takai Y, et al. Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci 2011;52:7944-8.
23. Radwan AE, Arcinue CA, Yang P, et al. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol 2013;251:1801-6.
24. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina 2010;30:260-6.
25. Yoshinaga N, Arimura N, Otsuka H, et al. NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. Lab Invest 2011;91:1277-90.
26. Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea 2006;25:224-7.